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Linkage studies of kindreds with the nevoid basal cell carci-
noma syndrome and the high frequency of chromosome 9 
allele loss in sporadic basal cell carcinomas indicate that chro-
mosome 9 may contain tumor suppressor genes important in 
the development of sporadic and familial basal cell carcino-
mas. The recent mapping of the Ferguson-Smith syndrome, 
which predisposes affected individuals to the development of 
multiple lesions histologically indistinguishable from squa-
mous cell carcinomas, suggests that tumor suppressor genes 
on 9q may also be important in the development of squamous 
cell neoplasms of the skin. Fifty-four non-melanoma skin 
cancers (24 basal cell carcinomas, 14 squamous cell carcino-
mas, and 16 cases of Bowen's disease) were examined for loss 
of heterozygosity on chromosome 9. Allelic loss at one or 
more loci on chromosome 9 was observed in 14 of 24 basal 
cell carcinomas, four of 14 squamous cell carcinomas, and 
Basal cell carcinomas (BCC) and squamous cell carcino-mas (SCC) of the skin are both derived from the same cell type, the keratinocyte, and in the majority of in-stances are causally related to ultraviolet radiation exposure [1]. The frequency of recognized genetic 
changes including mutations of the p53 tumor suppressor gene, is 
similar for both BCCs and SCCs [2- 6] . This suggests that other, as 
yet unidentified, genetic events are important in explaining the 
marked differences in biologic behavior between these two tumor 
types. 
Mapping studies of kindreds with the nevoid basal cell carcinoma 
syndrome (NBCCS) have recently shown evidence of linkage with 
genetic markers on chromosome 9q22 - 31 [7-9]. This disorder 
predisposes affected individuals to the development of multiple 
BCCs at an early age [10]. The finding of a high frequency of 
chromosome 9 allele loss in sporadic BCCs in one study [9] is in 
keeping with observations from other cancers such as colon and 
breast [11,12], where the sporadic tumors frequently show loss of 
the chromosome region that contains the gene implicated in the 
familial cancer. These findings indicate that the long arm of chro-
mosome 9 may contain one or more tumor suppressor genes impor-
tant in the development of sporadic and fami lial BCCs. Patients 
with the Ferguson-Smith syndrome are predisposed to the develop-
ment of multiple rapidly growing nodular lesions, which involute 
spontaneously leaving pitted scars and are histologically indistin-
guishable from SCCs [13] . This autosomal dominant disorder has 
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three of 16 cases of Bowen's disease. Allelic deletion of one or 
more 9q markers was seen in 14 basal cell carcinomas, three 
squamous cell carcinomas, and three cases of Bowen's disease. 
Five basal cell carcinomas had interstitial deletions and in one 
the breakpoint mapped within the nevoid basal cell carci-
noma syndrome locus. 9p loss occurred in three of nine in-
formative squamous cell carcinomas. Allelic deletion of 9p 
markers was not seen in 19 basal cell carcinomas and seven 
cases of Bowen's disease. These findings suggest that chro-
mosome 9 contains one or more tumor suppressor genes im-
portant in the development of both basal and squamous cell 
carcinomas of the skin. Key words: chromosome 9/basal cell 
carcinoma/squamous cell carcinoma/nevoid basal cell carcinoma 
syndrome/loss oJheterozygosity.] Invest Dermatoll 02:300-303, 
1994 
also recently been mapped to chromosome 9q [14] . This finding and 
the observation in other organs such as the lung and esophagus that 
histologically distinct tumor types arising in the same organ fre-
quently share common genetic changes [15,16] suggests that tumor 
suppressor genes on 9q may also be important in the development of 
SCCs of the skin. We have therefore examined and compared the 
frequency and pattern of chromosome 9 allele loss in sporadic BCCs 
and squamous cell neoplasms of the skin. 
METHODS 
Patients and Samples Twenty-four BCCs, 14 SCCs, and 16 cases of 
intra-epithelial carcinoma (Bowen's disease) were studied. All tumors were 
from sun-exposed sites. One BCC was a debulk specimen from a Mohs 
procedure and the remaining 23 BCCs were obtained from biopsies of solid 
BCCs 3-6 mm in diameter. Morphoeic and superficial BCCs were not 
examllled. Samples were collected prospectively after obtaining fu lly in-
formed consent. Tumor was dissected from clinically normal skin, snap 
frozen, and stored at-70·C. Clinical diagnosis was confirmed in all cases by 
histologic examination of the residual tumor. 
Analysis of Loss of Heterozygosity (LOH) DNA was extracted ac-
cording to standard methods [3]. Normal DNA was extracted from matched 
peripheral blood sample or from adjacent normal skin. For Southern blot 
analysis 5-10 Jl.g of normal and tumor DNA was digested with restriction 
endonucleases, size fractionated in 0.8% agarose and transferred onto nylon 
membranes. Probes were labeled by the random priming method. Mem-
branes were hybridized at 65 ·C and washed to a stringency of 0.1 X SSC, 
0.1 % sodium dodecylsulfate (SDS) at 65 ·C. Filters were exposed to Fuji XR 
film with intensifying screens for 1 - 5 d and blots scalUled using an LKB 
laser densitometer. Analysis of loss of heterozygosity using microsatellite 
polymorphisms was as follows: PCR was carried out in 10 Jl. l or 25 Jl.l 
reactions using 100 ng of DNA, 200 mM dNTPs, 1 pmol of each primer 
(one end-labeled with y32P adenosine triphosphate and 1 U ofTaqXL ON A 
polymerase (NBL, Cramlington, UK). Ten microliters ofloading buffer was 
added to each reaction, and samples were heat denatured and electrophor-
esed through 6% denaturing polyacrylamide gels. Gels were dried and ex-
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Table I. Chromosomal Location of Polymorphic DNA Probes and Microsatellite Markers Used to Study LOH 
Chromosome Location Locus' Probe/Primer Restriction Enzyme Heterozygosity Score 
9p21-23 D9S162 Microsatelliteb NA' 0.75 
D9S166 Microsatelliteb NA 0.82 
D9S9 pEKZ 130' MspI 0.33 9q13-21.1 
9q22.2-22.3 D9S12 Microsatellite' NA 0.70 
09S29 0.55 9q22.3 pLAMP 92d TaqI 
9q31 D9S160 Microsatelliteb NA 0.64 
9q34 D9S7 pEFD 126.3' MspI/TaqI 0.7 
• Loci are listed in linkage order from 9pter-9qter as described in the 1993 chromosome 9 workshop [20). 
I Weissenbach second-generation linkage markers [17) . 
'Human Genome mapping centre, U.K. 
, American Type Culture Collection, Rockville, USA. 
'NA, not applicable. 
posed to Fuji XR film for 1-12 h. Informative patients were identified and 
allelic loss scored. Restriction fragment length polymorphism (RFLP) 
markers and microsatellite markers used are listed in Table I. 
RESULTS 
Twenty-four BCCs, 14 SCCs, and 16 cases of Bowen's disease were 
examined for LOH on chromosome 9. The ability to detect LOH 
following PCR amplification of microsatellites was investigated 
using samples showing 9q allele loss on Southern blot analysis. In 
Fig 1, tumor DNA in sa~p~es ~84 and 227 s~ows loss of a band 
present in normal DNA mdlcatmg LOH at thiS locus. In samples 
184 and 14, allele loss at all informative loci is seen (Fig 2) using 
both RFLP markers (D9S7 and D9S29) and microsatellite markers 
(D9S12 and D9S1.60). Pati~nt 184 was uninf~rmative ~t D9S29 and 
patient 14 was unmformatlve at D9S12. An 1I1formatl~e result was 
obtained for at least one marker on chromosome 9q 111 all of the 
tumors examined. Nineteen of 24 BCCs, 12 of 14 SCCs, and seven 
of 16 cases of Bowen's disease were also informative for D9S162 
on 9p. Allelic deletion at one or more loci on chromosome 9 was 
observed in 14 of24 BCCs (58%), four of14 SCCs (28%), and three 
of 16 cases of Bowen's disease (19%). LOH of one or more 9q loci 
was seen in 14 BCCs, three SCCs, and three cases of Bowen's 
disease. Loss of the short arm of chromosome 9 (9p) was not seen in 
the 19 BCCs informative at D9S 162. Three of nine SCCs showed 
9p allelic loss. None of the seven cases of Bowen's disease showed 
LOH of 9p markers (Fig 3). 
Of the 14 BCCs showing 9q allele loss, seven (tumors 14, 15,78, 
184, 187,227,242) showed LOH for all informative markers sug-
gesting deletion of the entire long arm of chromosome 9. In two 
BCCs (12 and 189) that showed both proximal and distal 9q loss 
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Figure 1. Southern blot of MspI restricted DNA from tumor (T) and 
matched normal tissue (C), hybridized with probe pEFD126.3 (D9S7) 
mapped to distal 9q. 
there was insufficient DNA to confirm loss at the intervening loci. 
Interstitial deletioll3 of 9q were identified in five BCCs. Tumor 46 
showed loss of markers on proximal 9q (D9S166 and D9S9) but 
with retention of heterozygosity at the proximal flanking marker 
for the NBCCS locus, D9S12. A second deleted region was identi-
fied in this BCC with LOH at D9S160 and retention at the more 
distal loci D9S7. Further characterization of this deletion encom-
passing D9S160 using other microsatellites shows that the break-
point lies within the NBCCS locus (data not shown). Tumor 53 
also showed an interstitial deletion that includes the NBCCS locus. 
BCC 87 showed a terminal deletion of 9q distal to D9S29 and allelic 
deletion at D9S 166. We were unable to determine the extent of this 
deletion as intervening markers D9S9 and D9S12 were uninforma-
tive. In BCC 185 and 188 insufficient DNA was available for de-
tailed mapping of the region between D9S9 and D9S160. 
Two SCCs (193 and 235) showed 9p loss with retention ofhet-
erozygosity at proximal 9q loci. In SCC 235 deletion of D9S7 on 
terminal 9q was also seen. We were unable to determine the extent 
of the 9q loss as markers D9S29 and D9S160 were uninformative. 
SCC 197 showed 9p loss with retention of both proximal and distal 
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Figure 2. DNA from tumors (T) 184 and 14 with matched normal tissue 
(C) analyzed by Southern blotting (probe pEFD126.3 (D9S7). pLAMP 92 
(D9S29)]. and peR of microsatellite loci (D9S12 and D9S160). 
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Figure 3. Deletion map of chromosome 9. Diagrammatic representation of 
the pattern of allele loss in Bees, sees, and Bowen's disease showing loss of 
one or more chromosome 9 markers. 0, retention of heterozygosity; ., loss 
of heterozygosity;0, uninformative; ND, not determined. 
9q markers. In SCC 55 proximal 9q loss occurred with retention of 
heterozygosity on 9p and the distal 9q marker D9S160. Two cases 
of Bowen's disease showed interstitial deletions of9q. The extent of 
loss in the other case of Bowen's disease (232) could not be deter-
mined as flanking 9q markers and the 9p marker used were uninfor-
mative. None of 'the cases of Bowen's disease with 9q loss were 
informative for D9S162 on 9p. 
DISCUSSION 
We have shown that LO H of chromosome 9 markers occurs in both 
BCCs and SCCs of the skin. Our findings of 9q allele loss in 14 of 
24 BCCs confirms and extends the findings of Gailani et al who 
found allelic loss in 11 of 16 sporadic BCCs using a total of six 9q 
probes [9]. However, there are a number of important differences 
between the results presented by Gailani et al and the present work. 
This group reported 9p loss in four of eight BCCs whereas in our 
series 9p loss was not found in any of 19 informative tumors studied. 
This difference is statistically significant (p < 0.01). It is possible 
that this relates to other factors such as tumor size and/or histologic 
sub-type ofBCC examined, as it has been suggested that 9q loss in 
BCCs may be an early event in tumor development. The samples 
obtained by Gailani were obtained from tumors treated by Mohs 
surgery and are therefore likely to be large BCCs, whereas in the 
present study most samples were from smaller BCCs. An additional 
difference between the results of Gailani et al and those presented 
here is that the pattern of chromosome 9q allele loss was different. 
We found loss at D9S7 in 13 of 20 informative BCCs compared to 
one of five in the series of BCCs examined by Gailani. In view of the 
differences reported in loss of heterozygosity of9p, this difference is 
intriguing, but we cannot exclude the possibility that it is due to 
statistical sampling as only a small number of tumors were examined 
for LOH at this locus in the series reported by Gailani. Deletion 
mapping of the BCCs using six polymorphic markers on 9q identi-
fied five BCCs with interstitial deletions of 9q. Interestingly, in one 
BCC we identified two distinct deletions in the same tumor. The 
distal interstitial deletion in this tumor has a proximal breakpoint 
that lies within the disease locus for NBCCS. Further deletion 
mapping of this and other BCCs will allow better definition of the 
NBCCS locus. 
The role of tumor suppressor genes other than p53 in the devel-
opment of squamous cell carcinomas of the skin is not known. 
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
Three lines of evidence suggest that chromosome 9 may contain one 
or more tumor suppressor genes important in the development of 
human squamous cell carcinomas of the skin. Firstly, the Ferguson-
Smith syndrome has been mapped to chromosome 9q [14]. Sec-
ondly, a number of karyotyping studies of SCCs have identified 
cytogenetic changes on chromosome 9 [18,19]. Thirdly the high 
frequency of9q allele loss in sporadic BCCs [9], and the finding that 
in other human cancers histologically distinct tumor types arising in 
the same organ frequently show common genetic changes [15,16] . 
We report LO H of chromosome 9 alleles in sporadic squamous cell 
neoplasia of the skin, LOH being present in four of 14 informative 
SCCs (28%) and three of 16 (19%) cases of intra-epithelial carci-
noma (Bowen's disease) . The frequency of chromosome 9 allele loss 
in the squamous cell neoplasms in this study is likely to be an 
underestimate of the true prevalence as non-neoplastic stromal cell 
contamination may have masked allele loss in some of the samples. 
Two of the markers used, D9S29 and D9S 12, lie within the region 
that shows genetic linkage with NBCCS [7 - 9] and the Ferguson-
Smith syndrome [14] . One case of Bowen's disease showed loss at 
D9S29. The remaining patients were uninformative at D9S29 and 
D9S12 and we were therefore unable to determine if the deleted 
regions in the other squamous cell neoplasms included the region in 
genetic linkage with these syndromes. 
Our results show that loss of heterozygosity of chromosome 9 
alleles is a common finding in BCCs and SCCs of the skin. By 
reanalyzing samples showing LOH with RFLP markers by South-
ern blotting with DNA microsatellites, we have demonstrated that 
these highly polymorphic PCR based markers can be used to suc-
cessfully identify allele loss in small tissue samples. Loss of hetero-
zygosity of both 9q and 9p occurred in SCCs, but not in BCCs or 
Bowen's disease. The difference in pattern of LOH of chromosome 
9 markers between BCC and the SCCs may either reflect different 
targets of allelic deletion in these two histologic types of tumors or 
alternatively differences in the mechanisms by which LOH occurs 
in these tumors. Further deletion mapping on chromosome 9 using 
highly polymorphic markers is currently underway to determine 
whether the same target gene is involved in the development of 
non-melanoma skin cancers of different histologic types . 
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